share_log

《大行報告》花旗升國藥(01099.HK)目標價至30元 業績符預期復甦上軌道

AASTOCKS ·  Mar 27 11:38

花旗報告指,國藥(01099.HK)去年收入及淨利潤分別按年升8%及6.2%,大致符合該行及市場預期。管理層指業務持續從反貪復甦,預期今年藥物銷售收入增長較保健行業快2至3個百分點,符合公司早前的長期指引。管理層亦預期維持穩定毛利率、藥物服務收入加快增長及醫療設備業務增長加快。

該行調整對國藥今明兩年每股盈利預測1%至2%,上調對國藥目標價,由26元上調至30元,為今年預測市盈增長(PEG)率1倍,投資評級維持「買入」。

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment